About Gliknik - Board of Directors
David S. Block - Chairman
Skip Klein - Non-executive Director
Mr. Klein is currently Managing Director of Gauss Capital Advisors, LLC, a financial consulting and investment advisory firm focused on biopharmaceuticals, which he founded in March 1998. Mr. Klein currently serves on the board of directors of two public biotechnology companies: Isis Pharmaceuticals, Inc. and Savient Pharmaceuticals, Inc. as well as the Board of Directors of the Prospector Funds, Inc., an SEC registered investment company that manages two no-load mutual funds. He has previously served on the boards and Audit Committees of BioMarin Pharmaceutical, Inc.; Clinical Data, Inc.; Genaissance Pharmaceuticals, Inc.; Guilford Pharmaceuticals, Inc.; NPS Pharmaceuticals, Inc.; OSI Pharmaceuticals, Inc.; PDL BioPharma, Inc.; and Synbiotics, Inc. Mr. Klein also serves on the boards of private and non-profit entities. From 1989 to 1998, Mr. Klein was a health care investment analyst at T. Rowe Price Associates, Inc., where he was the founding portfolio manager of the T. Rowe Price Health Sciences Fund, Inc. He has previously served as a Venture Partner of Red Abbey Venture Partners, L.P. and of MPM Capital. Mr. Klein received a B.A., summa cum laude, in Economics from Yale University, and an MBA from the Graduate School of Business at Stanford University.
Raymond Schinazi, Ph.D., D.Sc. (Hon.) - Non-executive Director
Dr. Schinazi is the founder or co-founder of several biotechnology companies that progressed from startup through IPO, including Pharmasset Inc., Triangle Pharmaceuticals (acquired by Gilead Sciences in 2003), and Idenix Pharmaceuticals (54% acquired by Novartis in 2003). Dr. Schinazi founded RFS Pharma LLC in September 2004. Dr. Schinazi is best known for his pioneering work on d4T (stavudine, Zerit®), 3TC (lamivudine, Epivir®), FTC (emtricitabine, Emtriva&®), Telbivudine (LdT) , drugs that progressed through NDA and are now approved by the FDA, as well as for his work on D-D4FC (Reverset®), racemic FTC (Racivir®), and DAPD (amdoxovir), which are at various stages of clinical development. He is the Frances Winship Walters Professor of Pediatrics and Chemistry at Emory University and Georgia State University, respectively. He is also a Senior Research Career Scientist at the Atlanta Department of Veterans Affairs. He is the virology/pharmacology core co-director for the Emory Center for AIDS Research (CFAR). He has published over 400 peer-reviewed papers and seven books, holds more than 80 US patents, and is on the editorial board of several journals.